XML 41 R30.htm IDEA: XBRL DOCUMENT

Segment, Geographical and Other Revenue Information (Tables)

9 Months Ended

Sep. 30, 2020

The following tables provide financial information by our reportable business segments along with a reconciliation to consolidated income (loss) before income taxes (in thousands):


	Three months ended September 30, 2020						Three months ended September 30, 2019
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Revenues:
Product revenue	$	8,401	$	—	$	8,401	$	10,351	$	—	$	10,351
Research and development revenue	4,604		5,380		9,984		10,073		1,482		11,555
Total revenues	13,005		5,380		18,385		20,424		1,482		21,906
Costs and operating expenses:
Cost of product revenue	3,642		—		3,642		5,067		—		5,067
Research and development(1)	5,184		6,433		11,617		5,313		3,080		8,393
Selling, general and administrative(1)	2,675		515		3,190		2,037		690		2,727
Total segment costs and operating expenses	11,501		6,948		18,449		12,417		3,770		16,187
Income (loss) from operations	$	1,504	$	(1,568)	(64)		$	8,007	$	(2,288)	5,719
Corporate costs (2)					(5,483)						(4,912)
Depreciation and amortization					(528)						(471)
Income (loss) before income taxes					$	(6,075)					$	336

(1) Research and development expenses and Selling, general and administrative expenses exclude depreciation and amortization of finance leases.

(2) Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.


	Nine months ended September 30, 2020						Nine months ended September 30, 2019
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Revenues:
Product revenue	$	18,005	$	—	$	18,005	$	24,588	$	—	$	24,588
Research and development revenue	13,380		16,638		30,018		16,512		8,708		25,220
Total revenues	31,385		16,638		48,023		41,100		8,708		49,808
Costs and operating expenses:
Cost of product revenue	7,882		—		7,882		12,230		—		12,230
Research and development(1)	15,877		16,848		32,725		14,889		9,252		24,141
Selling, general and administrative(1)	7,395		1,728		9,123		6,499		1,768		8,267
Total segment costs and operating expenses	31,154		18,576		49,730		33,618		11,020		44,638
Income (loss) from operations	$	231	$	(1,938)	(1,707)		$	7,482	$	(2,312)	5,170
Corporate costs (2)					(16,526)						(15,185)
Depreciation and amortization					(1,526)						(1,273)
Loss before income taxes					$	(19,759)					$	(11,288)

(1) Research and development expenses and Selling, general and administrative expenses exclude depreciation and amortization of finance leases.

(2) Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.

The following tables provides stock-based compensation expense included in income (loss) from operations (in thousands):


	Three months ended September 30,
	2020								2019
	Performance Enzymes		Novel Biotherapeutics		Corporate cost		Total		Performance Enzymes		Novel Biotherapeutics		Corporate cost		Total
Stock-based compensation	$	839	$	132	$	1,013	$	1,984	$	736	$	225	$	771	$	1,732

	Nine months ended September 30,
	2020								2019
	Performance Enzymes		Novel Biotherapeutics		Corporate cost		Total		Performance Enzymes		Novel Biotherapeutics		Corporate cost		Total
Stock-based compensation	$	2,335	$	625	$	3,132	$	6,092	$	1,973	$	563	$	3,247	$	5,783

Schedule of customers that contributed 10% or more of total accounts receivable

Significant Customers

Customers that each accounted for 10% or more of our total revenues were as follows:


	Percentage of Total Revenues for the
	Three Months Ended September 30,		Nine Months Ended September 30,
	2020	2019	2020	2019
Customer A	23%	21%	21%	31%
Customer B	15%	*	13%	17%
Customer C	*	29%	11%	15%
Customer D	14%	*	22%	*
Customer E	13%	*	*	*

Customers that each accounted for 10% or more of accounts receivable had balances as of the periods presented as follows:


	Percentage of Accounts Receivables as of
	September 30, 2020	December 31, 2019
Customer A	36%	38%
Customer B	28%	10%
Customer D	14%	*
* Percentage was less than 10%

Schedule of revenues by geographical area

Geographic revenues are identified by the location of the customer and consist of the following (in thousands):


	Three Months Ended September 30,				Nine months ended September 30,
	2020		2019		2020		2019
Revenues
Americas	$	5,841	$	2,706	$	17,972	$	9,620
EMEA	4,889		12,205		14,175		24,672
APAC	7,655		6,995		15,876		15,516
Total revenues	$	18,385	$	21,906	$	48,023	$	49,808

Schedule of long-lived assets by geographical area

Identifiable long-lived assets by location was as follows (in thousands):


Long-lived assets	September 30, 2020		December 31, 2019
United States	$	7,289	$	6,282

Schedule of intangible assets and goodwill

Identifiable goodwill was as follows (in thousands):


	As of September 30, 2020 and December 31, 2019
	Performance Enzymes		Novel Biotherapeutics		Total
Goodwill	$	2,463	$	778	$	3,241